This is a prospective , epidemiological, multi-centre, phase IV study, approximately 5,000 patients who suffer with upper gastrointestinal tract symptoms. Each patient will be assessed for GERD with GerdQ Thai Version.

Inclusion Criteria:

• Provision of informed consent prior to any study specific procedures
• Female or male aged at least 18 years
• Patient must be having symptoms suggestive of upper gastrointestinal tract symptoms such as heart burn/ regurgitation

Exclusion Criteria:

• Involvement in the planning and /or conduct of the study (applies to both AstraZeneca staff and /or staff at study site
• Participation in a clinical study(excluding non-interventional study or registry) during the last 3 months

Primary care clinic